Maxpro Capital Acquisition (JMAC) Competitors $6.33 +0.29 (+4.72%) As of 08/25/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock JMAC vs. CGC, RNAC, FHTX, NGNE, DSGN, AVIR, CTNM, GLUE, DBVT, and VORShould you be buying Maxpro Capital Acquisition stock or one of its competitors? The main competitors of Maxpro Capital Acquisition include Canopy Growth (CGC), Cartesian Therapeutics (RNAC), Foghorn Therapeutics (FHTX), Neurogene (NGNE), Design Therapeutics (DSGN), Atea Pharmaceuticals (AVIR), Contineum Therapeutics (CTNM), Monte Rosa Therapeutics (GLUE), DBV Technologies (DBVT), and Vor Biopharma (VOR). These companies are all part of the "pharmaceutical products" industry. Maxpro Capital Acquisition vs. Its Competitors Canopy Growth Cartesian Therapeutics Foghorn Therapeutics Neurogene Design Therapeutics Atea Pharmaceuticals Contineum Therapeutics Monte Rosa Therapeutics DBV Technologies Vor Biopharma Maxpro Capital Acquisition (NASDAQ:JMAC) and Canopy Growth (NASDAQ:CGC) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and media sentiment. Does the media refer more to JMAC or CGC? In the previous week, Canopy Growth had 5 more articles in the media than Maxpro Capital Acquisition. MarketBeat recorded 5 mentions for Canopy Growth and 0 mentions for Maxpro Capital Acquisition. Canopy Growth's average media sentiment score of 0.47 beat Maxpro Capital Acquisition's score of 0.00 indicating that Canopy Growth is being referred to more favorably in the news media. Company Overall Sentiment Maxpro Capital Acquisition Neutral Canopy Growth Neutral Is JMAC or CGC more profitable? Maxpro Capital Acquisition has a net margin of 0.00% compared to Canopy Growth's net margin of -155.76%. Maxpro Capital Acquisition's return on equity of 0.00% beat Canopy Growth's return on equity.Company Net Margins Return on Equity Return on Assets Maxpro Capital AcquisitionN/A N/A N/A Canopy Growth -155.76%-89.93%-44.24% Which has better earnings and valuation, JMAC or CGC? Maxpro Capital Acquisition has higher earnings, but lower revenue than Canopy Growth. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMaxpro Capital AcquisitionN/AN/AN/AN/AN/ACanopy Growth$274.92M1.28-$429.86M-$3.03-0.49 Which has more volatility & risk, JMAC or CGC? Maxpro Capital Acquisition has a beta of 0.01, suggesting that its stock price is 99% less volatile than the S&P 500. Comparatively, Canopy Growth has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500. Do analysts prefer JMAC or CGC? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Maxpro Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Canopy Growth 2 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.33 Do institutionals and insiders hold more shares of JMAC or CGC? 73.2% of Maxpro Capital Acquisition shares are held by institutional investors. Comparatively, 3.3% of Canopy Growth shares are held by institutional investors. 19.3% of Maxpro Capital Acquisition shares are held by insiders. Comparatively, 0.2% of Canopy Growth shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. SummaryMaxpro Capital Acquisition and Canopy Growth tied by winning 5 of the 10 factors compared between the two stocks. Get Maxpro Capital Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for JMAC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding JMAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JMAC vs. The Competition Export to ExcelMetricMaxpro Capital AcquisitionHolding Offices IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$145.16M$226.73M$2.57B$9.76BDividend YieldN/A3.17%2.53%4.08%P/E RatioN/A0.1721.9926.03Price / SalesN/A528.2074.73103.94Price / CashN/A123.7024.1528.79Price / BookN/A8.4736.566.08Net IncomeN/A-$11.59M$27.57M$265.64M7 Day Performance11.64%5.65%1.45%3.11%1 Month Performance1.61%5.76%1.21%0.39%1 Year Performance4,486.96%167.46%26.23%18.52% Maxpro Capital Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JMACMaxpro Capital AcquisitionN/A$6.33+4.7%N/A+4,280.1%$145.16MN/A0.002,021News CoverageGap UpCGCCanopy Growth0.5713 of 5 stars$1.22+0.4%N/A-76.8%$293.82M$225.65M-0.403,150Gap UpRNACCartesian Therapeutics2.5509 of 5 stars$11.25+1.6%$40.00+255.6%-18.2%$292.50M$38.91M-0.2164Positive NewsFHTXFoghorn Therapeutics2.9058 of 5 stars$5.09-3.2%$10.67+109.6%-34.5%$288.02M$22.60M-4.28120Positive NewsNGNENeurogene2.1944 of 5 stars$19.65+0.2%$46.17+135.0%-42.8%$280.33M$930K-4.5690DSGNDesign Therapeutics0.076 of 5 stars$4.91+2.5%N/A+6.3%$279.62MN/A-4.3840AVIRAtea Pharmaceuticals1.7072 of 5 stars$3.52+0.4%$6.00+70.7%-6.2%$278.95MN/A-2.1870CTNMContineum Therapeutics3.2881 of 5 stars$9.82+10.7%$22.75+131.8%-48.2%$277.32M$50M-4.5031GLUEMonte Rosa Therapeutics2.006 of 5 stars$4.46+0.6%$15.33+244.2%-27.5%$275.39M$75.62M12.3990Gap UpDBVTDBV Technologies2.7749 of 5 stars$10.02+2.2%$14.75+47.3%+112.8%$274.31M$4.15M-2.1080Positive NewsGap UpVORVor Biopharma0.0897 of 5 stars$2.16-1.8%N/AN/A$273.63MN/A-0.16140 Related Companies and Tools Related Companies CGC Competitors RNAC Competitors FHTX Competitors NGNE Competitors DSGN Competitors AVIR Competitors CTNM Competitors GLUE Competitors DBVT Competitors VOR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:JMAC) was last updated on 8/26/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 30th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBREAKING: Meta, Apple and NASA rush to invest in new "E.I." techBig Tech and even NASA are racing to back a breakthrough known as “E.I. Tech,” set to launch September 1st. Ex...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maxpro Capital Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Maxpro Capital Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access